Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trialWilliam D. Tap, Andrew J. Wagner, Hans Gelderblom et al.|The Lancet|2019Cited by 472
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma NetworkGeorge D. Demetri, Jean‐Yves Blay, Cristina R. Antonescu et al.|Annals of Oncology|2020Cited by 145
Imaging of Liposarcoma: Classification, Patterns of Tumor Recurrence, and Response to TreatmentKevin N. O’Regan, Nikhil H. Ramaiya, Jyothi P. Jagannathan et al.|American Journal of Roentgenology|2011Cited by 78
Preclinical activity of selinexor, an inhibitor of XPO1, in sarcomaRobert Nakayama, Andrew J. Wagner, Yi-Xiang Zhang et al.|Oncotarget|2016Cited by 75
Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological CorrelatesCandace L. Haddox, Suzanne George, Michael J. Nathenson et al.|Clinical Cancer Research|2024Cited by 35